FDA approves 2006 strain of flu vaccine

Aug 03, 2006

The U.S. Food and Drug Administration has approved the manufacture of this year's seasonal influenza vaccine.

The vaccine is designed to fight new virus strains scientists believe are likely to cause flu in the Northern Hemisphere during 2006-07.

Each year influenza vaccine manufacturers submit information and samples to the FDA of the virus strains to be produced for the upcoming seasonal influenza season. This season's FDA-approved formulation is identical to that recommended by the World Health Organization. The formulation includes one strain that was used in last year's vaccine and two new strains.

Seasonal flu vaccines do not protect against avian influenza, which is caused by different viral strains.

The U.S. Centers for Disease Control and Prevention say up to 20 percent of the U.S. population is stricken by influenza annually, with about 200,000 people requiring hospitalization and approximately 36,000 people dying from the disease.

At high risk for serious flu complications are elderly people, children and people with certain chronic medical conditions.

Copyright 2006 by United Press International

Explore further: Life expectancy gap widens between those with mental illness and general population

add to favorites email to friend print save as pdf

Related Stories

Controversial 'bird flu' edits move ahead

Dec 22, 2011

Top US scientists on Wednesday defended their bid to stop details of a mutant bird flu virus from being published and called for global cooperation to ward off an uncontrollable pandemic.

Researchers develop mRNA based flu vaccine

Nov 26, 2012

(Phys.org)—A joint research effort by the Friedrich-Loeffler-Institute and pharmaceutical company CureVac, both based in Germany, has resulted in the creation of a new type of flu vaccine. The vaccine, as the team describes ...

Recommended for you

New sleeping pill poised to hit US markets

4 hours ago

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

User comments : 0

More news stories

If you can remember it, you can remember it wrong

(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...

B vitamins could delay dementia

(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...

Reducing caloric intake delays nerve cell loss

Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...

New sleeping pill poised to hit US markets

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Changing cancer's environment to halt its spread

By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces ...

New method for producing clean hydrogen

Duke University engineers have developed a novel method for producing clean hydrogen, which could prove essential to weaning society off of fossil fuels and their environmental implications.